Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) EBT Margin (2020 - 2025)

Ovid Therapeutics filings provide 6 years of EBT Margin readings, the most recent being 1345.82% for Q4 2025.

  • Quarterly EBT Margin rose 1352082.0% to 1345.82% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 339.33% through Mar 2026, up 421779.0% year-over-year, with the annual reading at 240.13% for FY2025, 443001.0% up from the prior year.
  • EBT Margin hit 1345.82% in Q4 2025 for Ovid Therapeutics, up from 9210.61% in the prior quarter.
  • Across five years, EBT Margin topped out at 5042.01% in Q2 2024 and bottomed at 107798.33% in Q3 2022.
  • Average EBT Margin over 5 years is 14449.63%, with a median of 8653.28% recorded in 2024.
  • Peak annual rise in EBT Margin hit 9747448bps in 2023, while the deepest fall reached -1845214bps in 2023.
  • Ovid Therapeutics' EBT Margin stood at 84.7% in 2021, then crashed by -29448bps to 24859.09% in 2022, then surged by 57bps to 10790.14% in 2023, then decreased by -13bps to 12175.0% in 2024, then surged by 111bps to 1345.82% in 2025.
  • Per Business Quant, the three most recent readings for OVID's EBT Margin are 1345.82% (Q4 2025), 9210.61% (Q3 2025), and 74.68% (Q2 2025).